

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

Date Published: Monday, 12 Feb 2024

DETAILED NEWS

- The addition of CymaBays investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gileads existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients.
- FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024.
-

KEY HIGHLIGHTS

- - The text discusses the integration of CymaBay's experimental leading product candidate, seladelpar into Gilead's existing liver portfolio.
- This product is meant for the treatment of primary biliary cholangitis (PBC) including pruritus.
- - This addition is in line with Gilead's ongoing commitment to provide transformational medicines for patients.
- - The US Food and Drug Administration (FDA) has granted priority review to this product.
- - There is an anticipated approval of this product in the U.S. market in the third quarter of 2024.
- - The text does not provide any specific reports, statistics, or numerical data related to the mentioned product or companies.

INSIGHTS

- - The text discusses the addition of CymaBay's investigational lead product, seladelpar, to Gilead's existing liver portfolio.

- ↪ Seladelpar is intended for the treatment of primary biliary cholangitis (PBC), including pruritus.
- ↪ - This development aligns with Gilead's long-standing commitment to bringing transformational medicines to patients, indicating a strategic move for the company to strengthen its portfolio in the liver disease treatment space.
- ↪ - The U.S. Food and Drug Administration (FDA) has granted Priority Review to this new product.
- ↪ This suggests its potential significance and value in the medical field, as Priority Review is typically designated to drugs that offer major advances in treatments or provide a treatment where none existed.
- ↪ - The anticipated approval of seladelpar in the U.S. is scheduled for the third quarter of 2024.
- ↪ This indicates a timeline for when this treatment might become available to patients.
- ↪ - There are no specific reports, statistics, or numerical data provided in the text.
- ↪ The focus is primarily on the strategic business move by Gilead and the potential impact of the new product on the market.